The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 450-456, April 2008

Development of a Combined Heart and Carotid Artery Transplant Model to Investigate the Impact of Acute Rejection on Cardiac Allograft Vasculopathy

  • Behzad Soleimani, MD, MRCP, FRCS(C-Th)

      Affiliations

    • Department of Cardiac Surgery, National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • ,
  • Fumin Fu, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • ,
  • Philip Lake, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • ,
  • Victor C. Shi, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
    • Corresponding Author InformationReprint requests: Victor C. Shi, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080. Telephone: 862-778-8300. Fax: 973-781-8265.

Received 26 July 2007; received in revised form 23 December 2007; accepted 12 January 2008.

Background

Cardiac allograft vasculopathy (CAV) is the leading cause of late allograft loss after heart transplantation. Although clinical studies are suggestive of an association between episodes of acute rejection and subsequent emergence of CAV, direct experimental evidence in support of a causal relationship is lacking.

Methods

We developed a new murine model of CAV in which a carotid artery and a heart graft are simultaneously transplanted into a single recipient. Transplants were performed across full or partial major histocompatibility complex (MHC) mismatched strain combinations. The heart grafts were either syngeneic with the carotid graft or from a third-party strain. Carotid arteries were harvested after 30 days and evaluated by morphometry and immunohistochemistry.

Results

In the fully mismatched combination, all heart grafts were rejected within 7 days, as determined by loss of pulsation. At 30 days, carotid allografts in the combined transplant group had significantly more intimal hyperplasia compared with isolated carotid allografts. The neointima consisted of abundant smooth muscle cells and leukocytes. Intimal hyperplasia was also significantly enhanced by acute rejection of the third-party donor heart. In the partial MHC mismatched combination, the heart graft survived indefinitely, and this was associated with diminished intimal hyperplasia in the cotransplanted carotid artery compared with the isolated carotid allograft.

Conclusion

We present direct experimental evidence that CAV is promoted by acute parenchymal rejection of the heart. This interaction between acute rejection and CAV is mediated by both allospecific and non-allospecific processes. Effective therapeutic strategy against CAV should therefore target non-allospecific mediators as well as prevent episodes of acute rejection.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was funded by grants from the British Heart Foundation and Novartis Pharmaceutical Corporation.

PII: S1053-2498(08)00043-0

doi:10.1016/j.healun.2008.01.015

The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 450-456, April 2008